{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:29:05Z","timestamp":1792801745769,"version":"4.5.0"},"reference-count":173,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008973","name":"University of Kurdistan","doi-asserted-by":"publisher","award":["IR.MUK.REC.1401.431"],"award-info":[{"award-number":["IR.MUK.REC.1401.431"]}],"id":[{"id":"10.13039\/501100008973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.biopha.2023.114824","type":"journal-article","created":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T17:59:11Z","timestamp":1683050351000},"page":"114824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["Mechanisms of CD8+ T cell exclusion and dysfunction in cancer resistance to anti-PD-(L)1"],"prefix":"10.1016","volume":"163","author":[{"given":"Keywan","family":"Mortezaee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal","family":"Majidpoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2023.114824_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114150","article-title":"Bypassing anti-PD-(L) 1 therapy: mechanisms and management strategies","volume":"158","author":"Mortezaee","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.biopha.2023.114824_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-022-29286-5","article-title":"The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity","volume":"13","author":"Maurer","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2023.114824_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-022-29342-0","article-title":"Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma","volume":"13","author":"Holm","year":"2022","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.biopha.2023.114824_bib4","doi-asserted-by":"crossref","first-page":"eabk3338","DOI":"10.1126\/sciadv.abk3338","article-title":"PTPN2 elicits cell autonomous and non\u2013cell autonomous effects on antitumor immunity in triple-negative breast cancer","volume":"8","author":"Goh","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.biopha.2023.114824_bib5","article-title":"CD8+ T Cells in SARS-CoV-2 induced disease and cancer-clinical perspectives","volume":"13","author":"Mortezaee","year":"2022","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2023.114824_bib6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0167-5699(99)01444-9","article-title":"Faces and phases of human CD8+ T-cell development","volume":"20","author":"Hamann","year":"1999","journal-title":"Immunol. Today"},{"issue":"7685","key":"10.1016\/j.biopha.2023.114824_bib7","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/nature25144","article-title":"Effector CD8 T cells dedifferentiate into long-lived memory cells","volume":"552","author":"Youngblood","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.biopha.2023.114824_bib8","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1365-2567.2010.03255.x","article-title":"T\u2010cell exhaustion: characteristics, causes and conversion","volume":"129","author":"Yi","year":"2010","journal-title":"Immunology"},{"key":"10.1016\/j.biopha.2023.114824_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.622509","article-title":"Exhausted CD8+ T cells in the tumor immune microenvironment: new pathways to therapy","volume":"11","author":"Jiang","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2023.114824_bib10","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","article-title":"Molecular signature of CD8+ T cell exhaustion during chronic viral infection","volume":"27","author":"Wherry","year":"2007","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.biopha.2023.114824_bib11","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T cell dysfunction in cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"issue":"7764","key":"10.1016\/j.biopha.2023.114824_bib12","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-019-1324-y","article-title":"TOX is a critical regulator of tumour-specific T cell differentiation","volume":"571","author":"Scott","year":"2019","journal-title":"Nature"},{"issue":"7109","key":"10.1016\/j.biopha.2023.114824_bib13","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2023.114824_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-27179-7","article-title":"LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade","volume":"12","author":"Liu","year":"2021","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2023.114824_bib15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2326-6066.CIR-21-0515","article-title":"Reversing T-cell exhaustion in cancer: lessons learned from PD-1\/PD-L1 immune checkpoint blockadeAnti\u2013PD-L1 checkpoint blockade","volume":"10","author":"Budimir","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.biopha.2023.114824_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-015-0501-6","article-title":"Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma","volume":"32","author":"Zhang","year":"2015","journal-title":"Med. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2023.114824_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-01027-5","article-title":"Regulation of PD-L1 expression in the tumor microenvironment","volume":"14","author":"Yi","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2023.114824_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110133","article-title":"B7x in cancer immunity and immunotherapy","volume":"118","author":"Mortezaee","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"10","key":"10.1016\/j.biopha.2023.114824_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1041","article-title":"2018 nobel prize in physiology or medicine","volume":"7","author":"Smyth","year":"2018","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.biopha.2023.114824_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114639","article-title":"HHLA2 immune-regulatory roles in cancer","volume":"162","author":"Mortezaee","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"7","key":"10.1016\/j.biopha.2023.114824_bib21","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.4049\/jimmunol.2000347","article-title":"A critical role of CD40 and CD70 signaling in cDC1s in expansion and antitumor efficacy of adoptively transferred tumor-specific T cells","volume":"205","author":"Oba","year":"2020","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2023.114824_bib22","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/cmi.2014.130","article-title":"Intratumoral dendritic cells in the anti-tumor immune response","volume":"12","author":"Liu","year":"2015","journal-title":"Cell. Mol. Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2023.114824_bib23","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ccell.2014.09.006","article-title":"Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells","volume":"26","author":"Ruffell","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2023.114824_bib24","first-page":"1","article-title":"CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer","author":"Seitz","year":"2022","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2023.114824_bib25","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ccell.2019.05.004","article-title":"Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors","volume":"35","author":"Dangaj","year":"2019","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.biopha.2023.114824_bib26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/jcb.27594","article-title":"Disruption of the redox balance with either oxidative or anti\u2010oxidative overloading as a promising target for cancer therapy","volume":"120","author":"Farhood","year":"2019","journal-title":"J. Cell. Biochem."},{"issue":"3","key":"10.1016\/j.biopha.2023.114824_bib27","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.clim.2010.01.014","article-title":"Enrichment of CCR6+ Foxp3+ regulatory T cells in the tumor mass correlates with impaired CD8+ T cell function and poor prognosis of breast cancer","volume":"135","author":"Xu","year":"2010","journal-title":"Clin. Immunol."},{"issue":"7","key":"10.1016\/j.biopha.2023.114824_bib28","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1053\/j.gastro.2007.03.102","article-title":"Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients","volume":"132","author":"Fu","year":"2007","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.biopha.2023.114824_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004605","article-title":"Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells","volume":"10","author":"Noyes","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"11","key":"10.1016\/j.biopha.2023.114824_bib30","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.biopha.2023.114824_bib31","doi-asserted-by":"crossref","first-page":"13703","DOI":"10.18632\/oncotarget.14626","article-title":"CTLA-4 positive breast cancer cells suppress dendritic cells maturation and function","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2023.114824_bib32","article-title":"(Im) maturity in Tumor Ecosystem","volume":"11","author":"Mortezaee","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2023.114824_bib33","doi-asserted-by":"crossref","first-page":"xii18","DOI":"10.1093\/annonc\/mdx238","article-title":"Mechanisms regulating T-cell infiltration and activity in solid tumors","volume":"28","author":"Lanitis","year":"2017","journal-title":"Ann. Oncol."},{"issue":"13","key":"10.1016\/j.biopha.2023.114824_bib34","doi-asserted-by":"crossref","first-page":"21539","DOI":"10.18632\/oncotarget.15368","article-title":"Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma","volume":"8","author":"de Coana","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2023.114824_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119627","article-title":"Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives","volume":"277","author":"Mortezaee","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2023.114824_bib36","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.3389\/fimmu.2019.01906","article-title":"CD8+ T lymphocyte and NK cell network: circuitry in the cytotoxic domain of immunity","volume":"10","author":"Uzhachenko","year":"2019","journal-title":"Front. Immunol."},{"issue":"18","key":"10.1016\/j.biopha.2023.114824_bib37","doi-asserted-by":"crossref","first-page":"eaax7881","DOI":"10.1126\/sciadv.aax7881","article-title":"Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti\u2013PD-1\/PD-L1 immunotherapy","volume":"6","author":"Noman","year":"2020","journal-title":"Sci. Adv."},{"issue":"626","key":"10.1016\/j.biopha.2023.114824_bib38","doi-asserted-by":"crossref","first-page":"eabf0992","DOI":"10.1126\/scitranslmed.abf0992","article-title":"TRIB3 reduces CD8+ T cell infiltration and induces immune evasion by repressing the STAT1-CXCL10 axis in colorectal cancer","volume":"14","author":"Shang","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.biopha.2023.114824_bib39","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ccell.2019.08.009","article-title":"Recruit or reboot? How does anti-PD-1 therapy change tumor-infiltrating lymphocytes?","volume":"36","author":"Callahan","year":"2019","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.biopha.2023.114824_bib40","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","article-title":"Clonal replacement of tumor-specific T cells following PD-1 blockade","volume":"25","author":"Yost","year":"2019","journal-title":"Nat. Med."},{"issue":"70","key":"10.1016\/j.biopha.2023.114824_bib41","doi-asserted-by":"crossref","first-page":"eabi5072","DOI":"10.1126\/sciimmunol.abi5072","article-title":"Spatially mapping the immune landscape of melanoma using imaging mass cytometry","volume":"7","author":"Moldoveanu","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.biopha.2023.114824_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.03.033","article-title":"Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche","author":"Baldominos","year":"2022","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.biopha.2023.114824_bib43","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3390\/cancers11040541","article-title":"Low CD8+ T cell infiltration and high PD-L1 expression are associated with level of CD44+\/CD133+ cancer stem cells and predict an unfavorable prognosis in pancreatic cancer","volume":"11","author":"Hou","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2023.114824_bib44","series-title":"Association of PAK4 expression with overall survival in patients with non-small cell lung cancer (NSCLC)","article-title":".","author":"Mamdani","year":"2022"},{"issue":"1","key":"10.1016\/j.biopha.2023.114824_bib45","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s43018-019-0003-0","article-title":"PAK4 inhibition improves PD-1 blockade immunotherapy","volume":"1","author":"Abril-Rodriguez","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.biopha.2023.114824_bib46","article-title":"PAK4 inhibition improves PD1 blockade immunotherapy in prostate cancer by increasing immune infiltration","author":"Su","year":"2022","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.biopha.2023.114824_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-27658-x","article-title":"GPR182 limits antitumor immunity via chemokine scavenging in mouse melanoma models","volume":"13","author":"Torphy","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2023.114824_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-04425-z","article-title":"Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade","volume":"9","author":"Ho","year":"2018","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.biopha.2023.114824_bib49","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/ni.3390","article-title":"Phosphatase PP2A is requisite for the function of regulatory T cells","volume":"17","author":"Apostolidis","year":"2016","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2023.114824_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-27620-x","article-title":"Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production and immune response","volume":"12","author":"Yen","year":"2021","journal-title":"Nat. Commun."},{"issue":"23","key":"10.1016\/j.biopha.2023.114824_bib51","doi-asserted-by":"crossref","first-page":"10619","DOI":"10.7150\/thno.44871","article-title":"CDK4\/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner","volume":"10","author":"Zhang","year":"2020","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.biopha.2023.114824_bib52","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","article-title":"A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade","volume":"175","author":"Jerby-Arnon","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.biopha.2023.114824_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-24112-w","article-title":"Molecular determinants of response to PD-L1 blockade across tumor types","volume":"12","author":"Banchereau","year":"2021","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.biopha.2023.114824_bib54","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1158\/2159-8290.CD-20-1540","article-title":"Inhibition of CDK4\/6 promotes CD8 T-cell memory formation","volume":"11","author":"Heckler","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2023.114824_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104010","article-title":"Immune effects of CDK4\/6 inhibitors in patients with HR+\/HER2\u2212 metastatic breast cancer: Relief from immunosuppression is associated with clinical response","volume":"79","author":"Scirocchi","year":"2022","journal-title":"EBioMedicine"},{"issue":"588","key":"10.1016\/j.biopha.2023.114824_bib56","doi-asserted-by":"crossref","first-page":"eaaz6804","DOI":"10.1126\/scitranslmed.aaz6804","article-title":"A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma","volume":"13","author":"Yang","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biopha.2023.114824_bib57","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3389\/fimmu.2020.01228","article-title":"Targeting nuclear LSD1 to reprogram cancer cells and reinvigorate exhausted T cells via a novel LSD1-EOMES switch","volume":"11","author":"Tu","year":"2020","journal-title":"Front. Immunol."},{"issue":"1_Supplement","key":"10.1016\/j.biopha.2023.114824_bib58","doi-asserted-by":"crossref","first-page":"119.13","DOI":"10.4049\/jimmunol.208.Supp.119.13","article-title":"Targeting LSD1 rescues MHC class I antigen presentation and promotes immune checkpoint blockade response in small cell lung cancer","volume":"208","author":"Nguyen","year":"2022","journal-title":"J. Immunol."},{"issue":"20","key":"10.1016\/j.biopha.2023.114824_bib59","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1158\/1078-0432.CCR-22-1128","article-title":"Inhibition of LSD1 with bomedemstat sensitizes small cell lung cancer to immune checkpoint blockade and T-Cell killing","volume":"28","author":"Hiatt","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.biopha.2023.114824_bib60","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41388-018-0451-5","article-title":"Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade","volume":"38","author":"Qin","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2023.114824_bib61","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/S0959-8049(22)00995-9","article-title":"TAS1440, a novel reversible LSD1 inhibitor, modulates immunosuppressive population and potentiates the antitumor efficacy of anti-PD-1 antibody therapy","volume":"174","author":"Shibutani","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2023.114824_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-022-01557-1","article-title":"LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer","volume":"21","author":"Shen","year":"2022","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2023.114824_bib63","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22708","article-title":"Enriched cancer stem cells, dense stroma, and cold immunity: Interrelated events in pancreatic cancer","volume":"35","author":"Mortezaee","year":"2021","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"1","key":"10.1016\/j.biopha.2023.114824_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-02696-6","article-title":"Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGF\u03b2 enhance the efficacy of cancer immunotherapy","volume":"9","author":"Ravi","year":"2018","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.biopha.2023.114824_bib65","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1172\/JCI128644","article-title":"Hedgehog signaling promotes tumor-associated macrophage polarization to suppress intratumoral CD8+ T cell recruitment","volume":"129","author":"Petty","year":"2019","journal-title":"J. Clin. Investig."},{"issue":"19","key":"10.1016\/j.biopha.2023.114824_bib66","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.3390\/cancers14194964","article-title":"Development of the novel bifunctional fusion protein BR102 that simultaneously targets PD-L1 and TGF-\u03b2 for anticancer immunotherapy","volume":"14","author":"Wu","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2023.114824_bib67","series-title":"Safety and activity of M7824, a bifunctional fusion protein targeting PD-L1 and TGF-\u03b2, in patients with HPV associated cancers","author":"Strauss","year":"2018"},{"key":"10.1016\/j.biopha.2023.114824_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2017.09.027","article-title":"Anti-PD-L1\/TGF\u03b2R2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis","author":"Grenga","year":"2018","journal-title":"Urol. Onocol.: Semin. Org. Investig."},{"issue":"1","key":"10.1016\/j.biopha.2023.114824_bib69","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/cac2.12244","article-title":"Anti\u2010PD\u2010L1\/TGF\u2010\u03b2R fusion protein (SHR\u20101701) overcomes disrupted lymphocyte recovery\u2010induced resistance to PD\u20101\/PD\u2010L1 inhibitors in lung cancer","volume":"42","author":"Cheng","year":"2022","journal-title":"Cancer Commun."},{"issue":"7","key":"10.1016\/j.biopha.2023.114824_bib70","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/nm.1982","article-title":"Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells","volume":"15","author":"Gattinoni","year":"2009","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.biopha.2023.114824_bib71","article-title":"Molecular predictors of response to pembrolizumab in thymic carcinoma","volume":"2","author":"He","year":"2021","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.biopha.2023.114824_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-19917-0","article-title":"Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy","volume":"11","author":"Wisdom","year":"2020","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.biopha.2023.114824_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109071","article-title":"Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy","volume":"35","author":"DeVito","year":"2021","journal-title":"Cell Rep."},{"issue":"64","key":"10.1016\/j.biopha.2023.114824_bib74","doi-asserted-by":"crossref","first-page":"eabi8800","DOI":"10.1126\/sciimmunol.abi8800","article-title":"Lack of CD8+ T cell effector differentiation during priming mediates checkpoint blockade resistance in non\u2013small cell lung cancer","volume":"6","author":"Horton","year":"2021","journal-title":"Sci. Immunol."},{"issue":"64","key":"10.1016\/j.biopha.2023.114824_bib75","doi-asserted-by":"crossref","first-page":"eabj8825","DOI":"10.1126\/sciimmunol.abj8825","article-title":"Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8+ T cell clone size and cytotoxicity","volume":"6","author":"Watson","year":"2021","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.biopha.2023.114824_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101134","article-title":"The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis","volume":"41","author":"Li","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"4","key":"10.1016\/j.biopha.2023.114824_bib77","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000515305","article-title":"Exploring markers of exhausted CD8 T cells to predict response to immune checkpoint inhibitor therapy for hepatocellular carcinoma","volume":"10","author":"Hsu","year":"2021","journal-title":"Liver Cancer"},{"key":"10.1016\/j.biopha.2023.114824_bib78","first-page":"1","article-title":"Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity","author":"Vignali","year":"2022","journal-title":"Nat. Immunol."},{"issue":"9","key":"10.1016\/j.biopha.2023.114824_bib79","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s41590-020-0725-2","article-title":"Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen","volume":"21","author":"Vardhana","year":"2020","journal-title":"Nat. Immunol."},{"issue":"6316","key":"10.1016\/j.biopha.2023.114824_bib80","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.biopha.2023.114824_bib81","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/s41590-019-0441-y","article-title":"PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+ CD38hi cells and anti-PD-1 resistance","volume":"20","author":"Verma","year":"2019","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2023.114824_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.103785","article-title":"PD-L1+ CD8+ T cells enrichment in lung cancer exerted regulatory function and tumor-promoting tolerance","volume":"25","author":"Zheng","year":"2022","journal-title":"Iscience"},{"issue":"1","key":"10.1016\/j.biopha.2023.114824_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-02187-8","article-title":"Ezh2 phosphorylation state determines its capacity to maintain CD8+ T memory precursors for antitumor immunity","volume":"8","author":"He","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2023.114824_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-022-03103-7","article-title":"TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS\/LKB1 mutant NSCLC in humanized mouse model","volume":"5","author":"Meraz","year":"2022","journal-title":"Commun. Biol."},{"issue":"2","key":"10.1016\/j.biopha.2023.114824_bib85","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","article-title":"Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/anti-CTLA-4 combined therapy","volume":"35","author":"Gide","year":"2019","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.biopha.2023.114824_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-24767-5","article-title":"A human CD137\u00d7 PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade","volume":"12","author":"Geuijen","year":"2021","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.biopha.2023.114824_bib87","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","article-title":"CD8+ T cell states in human cancer: insights from single-cell analysis","volume":"20","author":"Van der Leun","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2023.114824_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104353","article-title":"Neuropilin-1 cooperates with PD-1 in CD8+ T cells predicting outcomes in melanoma patients treated with anti-PD1","volume":"25","author":"Rossignol","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.biopha.2023.114824_bib89","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/jitc-2020-000967","article-title":"Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy","volume":"8","author":"Chuckran","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.biopha.2023.114824_bib90","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/s41590-020-0733-2","article-title":"Neuropilin-1 is a T cell memory checkpoint limiting long-term antitumor immunity","volume":"21","author":"Liu","year":"2020","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2023.114824_bib91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-11280-z","article-title":"Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1","volume":"10","author":"Leclerc","year":"2019","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.biopha.2023.114824_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102761","article-title":"MYC deficiency impairs the development of effector\/memory T lymphocytes","volume":"24","author":"Nozais","year":"2021","journal-title":"Iscience"},{"issue":"1","key":"10.1016\/j.biopha.2023.114824_bib93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-21736-w","article-title":"KRAS drives immune evasion in a genetic model of pancreatic cancer","volume":"12","author":"Ischenko","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2023.114824_bib94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00926-x","article-title":"CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38\u03b1\/MYC\/PD-L1 signaling in non-small cell lung cancer","volume":"13","author":"Wang","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2023.114824_bib95","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.cell.2017.10.022","article-title":"Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer","volume":"171","author":"Topper","year":"2017","journal-title":"Cell"},{"issue":"1_Supplement","key":"10.1016\/j.biopha.2023.114824_bib96","doi-asserted-by":"crossref","first-page":"182.32","DOI":"10.4049\/jimmunol.208.Supp.182.32","article-title":"Exploring the role of c-Myc in defining the fate of exhausted CD8 T cells","volume":"208","author":"Toumi","year":"2022","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.biopha.2023.114824_bib97","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2023.114824_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2022.04.003","article-title":"Glutaminase inhibition impairs CD8 T cell activation in STK11-\/Lkb1-deficient lung cancer","author":"Best","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.biopha.2023.114824_bib99","first-page":"1","article-title":"An anti-PD-1\u2013GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy","author":"Chan","year":"2022","journal-title":"Nat. Cancer"},{"issue":"22","key":"10.1016\/j.biopha.2023.114824_bib100","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1002\/cncr.33133","article-title":"First\u2010in\u2010human phase 1 study of MK\u20101248, an anti\u2013glucocorticoid\u2010induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors","volume":"126","author":"Geva","year":"2020","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2023.114824_bib101","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ni759","article-title":"Stimulation of CD25+ CD4+ regulatory T cells through GITR breaks immunological self-tolerance","volume":"3","author":"Shimizu","year":"2002","journal-title":"Nat. Immunol."},{"issue":"29","key":"10.1016\/j.biopha.2023.114824_bib102","doi-asserted-by":"crossref","first-page":"eaat7061","DOI":"10.1126\/sciimmunol.aat7061","article-title":"Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8+ T cell dysfunction and maintain memory phenotype","volume":"3","author":"Wang","year":"2018","journal-title":"Sci. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2023.114824_bib103","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jcmgh.2022.09.007","article-title":"GITR ligation improves Anti-PD1-mediated restoration of human MMR-Proficient colorectal carcinoma tumor-derived T cells","volume":"15","author":"Rakk\u00e9","year":"2023","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2023.114824_bib104","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1001\/jamaoncol.2019.3848","volume":"6","author":"Heinhuis","year":"2020","journal-title":"JAMA Oncol."},{"issue":"13_Supplement","key":"10.1016\/j.biopha.2023.114824_bib105","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1158\/1538-7445.AM2018-3820","article-title":"Novel PD-1\/GITRL bispecific fusion protein delivering concurrent T cell co-stimulation and checkpoint pathway inhibition","volume":"78","author":"Dovedi","year":"2018","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.biopha.2023.114824_bib106","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s43018-021-00208-6","article-title":"ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer","volume":"2","author":"Deng","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.biopha.2023.114824_bib107","first-page":"OF1","article-title":"Targeting ULK1 decreases IFN\u03b3-Mediated resistance to immune checkpoint inhibitors","author":"Fenton","year":"2023","journal-title":"Mol. Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2023.114824_bib108","first-page":"1","article-title":"USP12 downregulation orchestrates a protumourigenic microenvironment and enhances lung tumour resistance to PD-1 blockade","volume":"12","author":"Yang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2023.114824_bib109","article-title":"Progranulin promotes immune evasion of pancreatic adenocarcinoma through regulation of MHCI expression","author":"Cheung","year":"2021","journal-title":"bioRxiv"},{"issue":"2","key":"10.1016\/j.biopha.2023.114824_bib110","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/cbin.11506","article-title":"Redox tolerance and metabolic reprogramming in solid tumors","volume":"45","author":"Mortezaee","year":"2021","journal-title":"Cell Biol. Int."},{"issue":"450","key":"10.1016\/j.biopha.2023.114824_bib111","doi-asserted-by":"crossref","first-page":"eaar3342","DOI":"10.1126\/scitranslmed.aar3342","article-title":"MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma","volume":"10","author":"Rodig","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"7681","key":"10.1016\/j.biopha.2023.114824_bib112","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nature24473","article-title":"A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy","volume":"551","author":"\u0141uksza","year":"2017","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.biopha.2023.114824_bib113","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ccell.2017.07.006","article-title":"Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade","volume":"32","author":"Saha","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2023.114824_bib114","article-title":"Exosome CTLA-4 regulates PTEN\/CD44 signal pathway in spleen deficiency internal environment to promote invasion and metastasis of hepatocellular carcinoma","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2023.114824_bib115","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.actbio.2020.08.008","article-title":"Anti-CTLA-4 antibody-functionalized dendritic cell-derived exosomes targeting tumor-draining lymph nodes for effective induction of antitumor T-cell responses","volume":"115","author":"Dai Phung","year":"2020","journal-title":"Acta Biomater."},{"issue":"1","key":"10.1016\/j.biopha.2023.114824_bib116","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1038\/s41467-022-29286-5","article-title":"The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity","volume":"13","author":"Maurer","year":"2022","journal-title":"Nat. Commun."},{"issue":"12_Supplement","key":"10.1016\/j.biopha.2023.114824_bib117","doi-asserted-by":"crossref","first-page":"CT041","DOI":"10.1158\/1538-7445.AM2022-CT041","article-title":"Abstract CT041: monotherapy dose escalation of davoceticept (ALPN-202), a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1)","volume":"82","author":"Millward","year":"2022","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2023.114824_bib118","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1261779","article-title":"Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer","volume":"6","author":"Shayan","year":"2017","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.biopha.2023.114824_bib119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0814-7","article-title":"PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma","volume":"7","author":"Ma","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2023.114824_bib120","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1158\/0008-5472.CAN-16-0274","article-title":"Tim-3 expression on tumor-infiltrating PD-1+ CD8+ T cells correlates with poor clinical outcome in renal cell carcinoma","volume":"77","author":"Granier","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2023.114824_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2021.104287","article-title":"Galectin-9 as a biomarker of disease severity","volume":"361","author":"Moar","year":"2021","journal-title":"Cell. Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2023.114824_bib122","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/14737140.2021.1865814","article-title":"TIM-3 pathway dysregulation and targeting in cancer","volume":"21","author":"Zeidan","year":"2021","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"10","key":"10.1016\/j.biopha.2023.114824_bib123","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J. Exp. Med."},{"issue":"16_Supplement","key":"10.1016\/j.biopha.2023.114824_bib124","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1158\/1538-7445.AM2020-2270","article-title":"RG7769 (PD1-TIM3), a novel heterodimeric avidity-driven T cell specific PD-1\/TIM-3 bispecific antibody lacking Fc-mediated effector functions for dual checkpoint inhibition to reactivate dysfunctional T cells","volume":"80","author":"Deak","year":"2020","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.biopha.2023.114824_bib125","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1158\/1078-0432.CCR-20-4405","article-title":"Blocking TIM-3 in treatment-refractory advanced solid tumors: a phase Ia\/b study of LY3321367 with or without an anti-PD-L1 antibody","volume":"27","author":"Harding","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.biopha.2023.114824_bib126","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1158\/1078-0432.CCR-20-3716","article-title":"Safety and immunogenicity of LY3415244, a bispecific antibody against TIM-3 and PD-L1, in patients with advanced solid tumors","volume":"27","author":"Hellmann","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2023.114824_bib127","article-title":"LAG3-PD-1 Combo Overcome the Disadvantage of Drug Resistance","volume":"12","author":"Wei","year":"2022","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2023.114824_bib128","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune EscapeLAG-3 and PD-1 synergistically prevent antitumor immunity","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res."},{"issue":"608","key":"10.1016\/j.biopha.2023.114824_bib129","doi-asserted-by":"crossref","first-page":"eabf5107","DOI":"10.1126\/scitranslmed.abf5107","article-title":"LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade","volume":"13","author":"Shen","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"11","key":"10.1016\/j.biopha.2023.114824_bib130","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1158\/2326-6066.CIR-19-0146","article-title":"PD-1 and LAG-3 dominate checkpoint receptor\u2013mediated T-cell inhibition in renal cell CarcinomaPD-1 and LAG-3 in renal cell carcinoma","volume":"7","author":"Zelba","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.biopha.2023.114824_bib131","article-title":"313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART\u00ae molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms","author":"Patel","year":"2020","journal-title":"BMJ Spec. J."},{"issue":"13_Supplement","key":"10.1016\/j.biopha.2023.114824_bib132","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1158\/1538-7445.AM2018-2719","article-title":"Dual blockade of PD-L1 and LAG-3 with FS118, a unique bispecific antibody, induces CD8+ T-cell activation and modulates the tumor microenvironment to promote antitumor immune responses","volume":"78","author":"Kraman","year":"2018","journal-title":"Cancer Res."},{"issue":"13_Supplement","key":"10.1016\/j.biopha.2023.114824_bib133","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1158\/1538-7445.AM2019-2399","article-title":"LAG-3\/PD-L1 mAb2 can overcome PD-L1-mediated compensatory upregulation of LAG-3 induced by single-agent checkpoint blockade","volume":"79","author":"Faroudi","year":"2019","journal-title":"Cancer Res."},{"issue":"459","key":"10.1016\/j.biopha.2023.114824_bib134","doi-asserted-by":"crossref","first-page":"eaat7807","DOI":"10.1126\/scitranslmed.aat7807","article-title":"The hallmarks of successful anticancer immunotherapy","volume":"10","author":"Galluzzi","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"7058","key":"10.1016\/j.biopha.2023.114824_bib135","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nature03987","article-title":"Pathophysiological consequences of VEGF-induced vascular permeability","volume":"437","author":"Weis","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2023.114824_bib136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-020-07169-6","article-title":"AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer","volume":"20","author":"Antoniotti","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2023.114824_bib137","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-21-4141","article-title":"Cancer-Associated fibroblasts suppress CD8+ T-cell infiltration and confer resistance to immune-checkpoint blockade","author":"Jenkins","year":"2022","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.biopha.2023.114824_bib138","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2023.114824_bib139","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1053\/j.gastro.2013.07.025","article-title":"Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma","volume":"145","author":"Ene\u2013Obong","year":"2013","journal-title":"Gastroenterology"},{"issue":"19","key":"10.1016\/j.biopha.2023.114824_bib140","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1158\/1078-0432.CCR-18-0205","article-title":"Cancer-Associated fibroblasts affect intratumoral CD8+ and FoxP3+ T Cells Via IL6 in the tumor MicroenvironmentCAFs affect tumor-infiltrating lymphocytes Via IL6","volume":"24","author":"Kato","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.biopha.2023.114824_bib141","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005543","article-title":"Anti-TGF-\u03b2\/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer","volume":"10","author":"Yi","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.biopha.2023.114824_bib142","doi-asserted-by":"crossref","DOI":"10.4161\/onci.26788","article-title":"The desmoplastic stroma of pancreatic cancer is a barrier to immune cell infiltration","volume":"2","author":"Watt","year":"2013","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.biopha.2023.114824_bib143","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/MPA.0000000000001261","article-title":"Desmoplasia in lymph node metastasis of pancreatic adenocarcinoma reveals activation of cancer-associated fibroblasts pattern and T-helper 2 immune cell infiltration","volume":"48","author":"Nizri","year":"2019","journal-title":"Pancreas"},{"issue":"7","key":"10.1016\/j.biopha.2023.114824_bib144","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/s41580-019-0123-5","article-title":"Metabolic regulation of cell growth and proliferation","volume":"20","author":"Zhu","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2023.114824_bib145","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.660944","article-title":"Hypoxia supports differentiation of terminally exhausted CD8 T cells","volume":"12","author":"Bannoud","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2023.114824_bib146","article-title":"Modified hypoxia-inducible factor expression in CD8+ T cells increases antitumor efficacy","author":"Johnson","year":"2021","journal-title":"Cancer Immunol. Res."},{"issue":"11","key":"10.1016\/j.biopha.2023.114824_bib147","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1016\/j.celrep.2017.08.071","article-title":"Culturing CTLs under hypoxic conditions enhances their cytolysis and improves their anti-tumor function","volume":"20","author":"Gropper","year":"2017","journal-title":"Cell Rep."},{"issue":"11","key":"10.1016\/j.biopha.2023.114824_bib148","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/ni.2714","article-title":"Hypoxia-inducible factors enhance the effector responses of CD8+ T cells to persistent antigen","volume":"14","author":"Doedens","year":"2013","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2023.114824_bib149","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1158\/1078-0432.CCR-18-2882","article-title":"Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan\u2013Kynurenine\u2013Aryl hydrocarbon AxisTrp\u2013Kyn\u2013AhR immunotherapy","volume":"25","author":"Labadie","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.biopha.2023.114824_bib150","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bjd.13100","article-title":"Peritumoral indoleamine 2, 3\u2013dioxygenase expression in melanoma: an early marker of resistance to immune control?","volume":"171","author":"Chevolet","year":"2014","journal-title":"Br. J. Dermatol."},{"issue":"200","key":"10.1016\/j.biopha.2023.114824_bib151","doi-asserted-by":"crossref","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.biopha.2023.114824_bib152","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/cas.12445","article-title":"Indoleamine 2, 3\u2013dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment","volume":"105","author":"Tanizaki","year":"2014","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.biopha.2023.114824_bib153","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1182\/blood-2005-08-3507","article-title":"CD25 and indoleamine 2, 3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition","volume":"108","author":"von Bergwelt-Baildon","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.biopha.2023.114824_bib154","first-page":"3827","article-title":"Gene silencing of indoleamine 2, 3\u2013dioxygenase 1 inhibits lung cancer growth by suppressing T\u2011cell exhaustion","volume":"19","author":"Shang","year":"2020","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.biopha.2023.114824_bib155","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41392-022-01127-3","article-title":"Tobacco carcinogen induces tryptophan metabolism and immune suppression via induction of indoleamine 2, 3-dioxygenase 1","volume":"7","author":"Liang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2023.114824_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106506","article-title":"Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer","volume":"84","author":"Wei","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"7","key":"10.1016\/j.biopha.2023.114824_bib157","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20130066","article-title":"Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4","volume":"210","author":"Holmgaard","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biopha.2023.114824_bib158","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2051-1426-2-3","article-title":"Mechanism of tumor rejection with doublets of CTLA-4, PD-1\/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment","volume":"2","author":"Spranger","year":"2014","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2023.114824_bib159","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1038\/s41467-020-17750-z","article-title":"Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine","volume":"11","author":"Campesato","year":"2020","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2023.114824_bib160","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.immuni.2022.01.006","article-title":"Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity","volume":"55","author":"Hezaveh","year":"2022","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.biopha.2023.114824_bib161","first-page":"1-1","article-title":"Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models","volume":"3","author":"Spahn","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2023.114824_bib162","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.canlet.2018.05.005","article-title":"Indoleamine 2, 3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells","volume":"431","author":"Li","year":"2018","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.biopha.2023.114824_bib163","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000605","article-title":"Peptide vaccination directed against IDO1-expressing immune cells elicits CD8+ and CD4+ T-cell-mediated antitumor immunity and enhanced anti-PD1 responses","volume":"8","author":"Dey","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2023.114824_bib164","first-page":"1","article-title":"Dysregulated metabolism: a friend-to-foe skewer of macrophages","author":"Mortezaee","year":"2022","journal-title":"Int. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2023.114824_bib165","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ccell.2022.01.001","article-title":"Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments","volume":"40","author":"Kumagai","year":"2022","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.biopha.2023.114824_bib166","first-page":"5726","article-title":"Increased lactate in AML blasts upregulates TOX expression, leading to exhaustion of CD8+ cytolytic T cells","volume":"11","author":"Chen","year":"2021","journal-title":"Am. J. Cancer Res."},{"issue":"11","key":"10.1016\/j.biopha.2023.114824_bib167","doi-asserted-by":"crossref","first-page":"6047","DOI":"10.1073\/pnas.1920413117","article-title":"Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8+ T cell stemness and antitumor immunity","volume":"117","author":"Hermans","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"674","key":"10.1016\/j.biopha.2023.114824_bib168","doi-asserted-by":"crossref","first-page":"eabb1269","DOI":"10.1126\/scisignal.abb1269","article-title":"Interleukin-7 protects CD8+ T cells from adenosine-mediated immunosuppression","volume":"14","author":"Koyas","year":"2021","journal-title":"Sci. Signal."},{"issue":"1","key":"10.1016\/j.biopha.2023.114824_bib169","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0719-5","article-title":"Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells","volume":"7","author":"Mastelic-Gavillet","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2023.114824_bib170","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/4093214","article-title":"Adenosine generated by regulatory T cells induces CD8+ T cell exhaustion in gastric cancer through A2aR pathway","volume":"2019","author":"Shi","year":"2019","journal-title":"BioMed. Res. Int."},{"issue":"35","key":"10.1016\/j.biopha.2023.114824_bib171","doi-asserted-by":"crossref","first-page":"13132","DOI":"10.1073\/pnas.0605251103","article-title":"A2A adenosine receptor protects tumors from antitumor T cells","volume":"103","author":"Ohta","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7652","key":"10.1016\/j.biopha.2023.114824_bib172","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.biopha.2023.114824_bib173","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/s41590-021-00982-6","article-title":"Differentiation of exhausted CD8+ T cells after termination of chronic antigen stimulation stops short of achieving functional T cell memory","volume":"22","author":"Tonnerre","year":"2021","journal-title":"Nat. Immunol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223006145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223006145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T17:55:01Z","timestamp":1780336501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223006145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":173,"alternative-id":["S0753332223006145"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114824","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms of CD8+ T cell exclusion and dysfunction in cancer resistance to anti-PD-(L)1","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114824","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114824"}}